VFY — Vitrafy Life Sciences Balance Sheet
0.000.00%
- AU$77.90m
- AU$78.29m
- AU$0.07m
Annual balance sheet for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 7.38 | 0.963 | 1.72 | 6.41 | 19.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.747 | 1.97 | 2.18 | 2.24 | 1.66 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 8.3 | 3.49 | 3.9 | 9.03 | 31.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.207 | 0.879 | 1.03 | 0.746 | 0.593 |
Total Assets | 8.51 | 4.37 | 4.93 | 9.78 | 31.8 |
Accounts Payable | |||||
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.544 | 11.3 | 19 | 33.9 | 2.72 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.23 | 11.6 | 19.6 | 34.4 | 3.08 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.285 | -7.27 | -14.6 | -24.6 | 28.8 |
Total Liabilities & Shareholders' Equity | 8.51 | 4.37 | 4.93 | 9.78 | 31.8 |
Total Common Shares Outstanding |